PEDIATRICS Vol. 98 No. 4 October 1996, pp. 763-769
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schertz, M.
Right arrow Articles by Bienkowski, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schertz, M.
Right arrow Articles by Bienkowski, R. S.

Predictors of Weight Loss in Children With Attention Deficit Hyperactivity Disorder Treated With Stimulant Medication

Mitchell Schertz MD1, Andrew R. Adesman MD1, Nancy E. Alfieri RN1, and Robert S. Bienkowski PhD2

1 Divison of Developmental and Behavioral Pediatrics, Schneider Children's Hospital, Long Island Jewish Medical Center, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, New York 11040
2 Pediatric Research Center, Schneider Children's Hospital, Long Island Jewish Medical Center, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, New York 11040

Objective. A retrospective study was undertaken to examine predictors of weight loss in children with attention deficit hyperactivity disorder (ADHD) treated with stimulant medication.

Design. Children diagnosed with ADHD and treated with methylphenidate hydrochloride (MPH) or dextroamphetamine sulfate (DEX) for at least 5 months were identified by retrospective chart review. Analyses were performed on 32 children (29 boys) treated with MPH and 28 children (25 boys) treated with DEX. Variables examined included pretreatment weight, pretreatment body mass index (BMI), duration of treatment, total daily dose, and weight-adjusted dose.

Results. The MPH-treated group was initially seen at a mean age (± standard deviation) of 7.5 years (±2.1). Mean duration of follow-up was 11.2 months (±3.8). Mean total daily dose was 25.5 mg (±8.2) and mean weight-adjusted dose was 1.0 mg/kg/day (±.5). Mean change in weight as expressed in z scores was -0.4 SD (±.7). The DEX-treated group was initially seen at a mean age of 9.3 years (±2.7). Mean duration of follow-up was 10.8 months (±4.1). Mean total daily dose was 14.9 mg (±8.2) and mean weight-adjusted dose was .5 mg/kg/day (±.3). Mean change in weight was -0.6 SD (±.6). Although the MPH group was younger than the DEX group, there were no between-group differences in weight or height either before treatment or at follow-up when adjusted for age and gender. Using linear regression analysis, significant correlations were found between pretreatment weight and change in weight for both the MPH-treated group (r = .63) and the DEX-treated group (r = .47). Stepwise multiple-regression analysis indicated that pretreatment age, weight-adjusted dose, and duration of follow-up did not significantly contribute to the variance in change of weight for either the MPH- or DEX-treated groups. To adjust for height, changes in BMI were also analyzed. For both medication groups, no differences were found between the heavier (BMIge50%) and thinner (BMI <50%) children in duration of follow up, total daily dose, or weight-adjusted dose. When the medication groups were combined, a greater proportion of heavier children experienced a decrease relative to their predicted BMI compared with thinner children (80% vs 52%). Comparisons of mean BMI slopes revealed that the heavier group experienced an absolute decrease in their BMI (-.139) in contrast to the thinner group (+.014) (t = 2.70).

Conclusions. Pretreatment weight, adjusted for age, gender, and height, is a significant predictor of weight loss in children with ADHD treated with either MPH or DEX. In contrast, pretreatment age, duration of treatment, and weight-adjusted dose were not found to be significant predictors.

Submitted on August 3, 1995
Accepted on November 30, 1995




This article has been cited by other articles:


Home page
 PediatricsHome page
M. E. Waring and K. L. Lapane
Overweight in Children and Adolescents in Relation to Attention-Deficit/Hyperactivity Disorder: Results From a National Sample
Pediatrics, July 1, 2008; 122(1): e1 - e6.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
G. S Goldfield, C. Lorello, and E. Doucet
Methylphenidate reduces energy intake and dietary fat intake in adults: a mechanism of reduced reinforcing value of food?
Am. J. Clinical Nutrition, August 1, 2007; 86(2): 308 - 315.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
D. L. Hurst, W. A. Lajara-Nanson, P. Dinakar, and R. B. Schiffer
Retrospective Review of Modafinil Use for Cerebral Palsy
J Child Neurol, December 1, 2004; 19(12): 948 - 951.
[Abstract] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
L. H Epstein, S. M Wright, R. A Paluch, J. J Leddy, L. W Hawk Jr, J. L Jaroni, F. G Saad, S. Crystal-Mansour, P. G Shields, and C. Lerman
Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers
Am. J. Clinical Nutrition, July 1, 2004; 80(1): 82 - 88.
[Abstract] [Full Text] [PDF]

Home page
 Pediatr. Rev.Home page
S. V. Joshi and H. M. Adam
ADHD, Growth Deficits, and Relationships to Psychostimulant Use
Pediatr. Rev., February 1, 2002; 23(2): 67 - 68.
[Full Text] [PDF]

Home page
 PediatricsHome page
Subcommittee on Attention-Deficit/Hyperactivity Di and Committee on Quality Improvement
Clinical Practice Guideline: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity Disorder
Pediatrics, October 1, 2001; 108(4): 1033 - 1044.
[Abstract] [Full Text] [PDF]